Shares of drug firm Jubilant Life Sciences rose by 6 per cent on June 6, as the company received final approval from the US health regulator for generic Levetiracetam injection, used for treating epilepsy, in the American market.
The stock climbed 5.96 per cent to Rs 374 on BSE. At NSE, shares of the company jumped 6 per cent to Rs 374.45.
The company has received abbreviated new drug application (ANDA) final approval for Levetiracetam injection USP, 500 mg/5 mL (100 mg/mL) from the United States Food and Drug Administration (USFDA), Jubilant Life Sciences had said in a BSE filing on June 3.
- Glenmark gets USFDA nod for contraceptive tablets
- Jubilant Life gets warning letter from US drug regulator
- Jubilant Life Sciences shares plunge after FDA warning for US plant
- Sun Pharma gets USFDA nod for testosterone cypionate injection
- Strides Arcolab stock at record high
- Strides Arcolab gets USFDA nod for Adenosine
The company’s product is the generic version of UCB’s Keppra injection in the same strength, it added.
“As on March 31, 2016, Jubilant Life Sciences had a total of 739 filings for formulations, of which 517 have been approved in various regions globally. These include 72 ANDAs filed in the US, of which 44 have been approved and 46 Dossier filings in Europe,” the company had said.